ISRN endocrinology最新文献

筛选
英文 中文
Do surgical interventions influence psychosexual and cosmetic outcomes in women with disorders of sex development? 手术干预会影响性发育障碍女性的性心理和美容效果吗?
ISRN endocrinology Pub Date : 2012-01-01 Epub Date: 2012-03-05 DOI: 10.5402/2012/276742
Nina Callens, Yvonne G van der Zwan, Stenvert L S Drop, Martine Cools, Catharina M Beerendonk, Katja P Wolffenbuttel, Arianne B Dessens
{"title":"Do surgical interventions influence psychosexual and cosmetic outcomes in women with disorders of sex development?","authors":"Nina Callens, Yvonne G van der Zwan, Stenvert L S Drop, Martine Cools, Catharina M Beerendonk, Katja P Wolffenbuttel, Arianne B Dessens","doi":"10.5402/2012/276742","DOIUrl":"10.5402/2012/276742","url":null,"abstract":"<p><p>Clinical practice developed to promote psychosexual well-being in DSD is under scrutiny. Although techniques for genital surgery have much improved lately, long-term studies on psychosexual functioning and cosmetic outcome on which to base treatment and counseling are scarce. We studied 91 women with a DSD. Feminizing surgery was performed in 64% of the women; in 60% of them, resurgery in puberty was needed after a single-stage procedure. Both patients and gynecologists were satisfied with the cosmetic appearance of the genitalia. However, forty percent of these females experienced sexuality-related distress and 66% was at risk for developing a sexual dysfunction, whether they had surgery or not. Recognizing the difficulty of accurate assessment, our data indicate that feminizing surgery does not seem to improve nor hamper psychosexual outcome, especially in patients with severe virilization.</p>","PeriodicalId":89576,"journal":{"name":"ISRN endocrinology","volume":"2012 ","pages":"276742"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3313564/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30540326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The management of type 2 diabetic patients with hypoglycemic agents. 使用降糖药物管理 2 型糖尿病患者。
ISRN endocrinology Pub Date : 2012-01-01 Epub Date: 2012-04-04 DOI: 10.5402/2012/601380
G P Carnevale Schianca, D Sola, L Rossi, G P Fra, E Bartoli
{"title":"The management of type 2 diabetic patients with hypoglycemic agents.","authors":"G P Carnevale Schianca, D Sola, L Rossi, G P Fra, E Bartoli","doi":"10.5402/2012/601380","DOIUrl":"10.5402/2012/601380","url":null,"abstract":"<p><p>Aims and Scope. Aims of the paper are to suggest the best treatment to improve the glycemic control in patients with Type 2 diabetes using hypoglycemic agents, in particularly, we think that every patient is different from another one in terms of BMI, family history, duration of the disease and so on. We propose for every clinical aspect the best hypoglycemic agents to use, considering the scientific evidence and physiopathology.</p>","PeriodicalId":89576,"journal":{"name":"ISRN endocrinology","volume":"2012 ","pages":"601380"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30610826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatic dysfunction in hospitalized patients with acute thyrotoxicosis: a decade of experience. 急性甲状腺毒症住院患者肝功能障碍:十年的经验。
ISRN endocrinology Pub Date : 2012-01-01 Epub Date: 2012-11-29 DOI: 10.5402/2012/325092
Richard M Elias, Diana S Dean, Gregory W Barsness
{"title":"Hepatic dysfunction in hospitalized patients with acute thyrotoxicosis: a decade of experience.","authors":"Richard M Elias,&nbsp;Diana S Dean,&nbsp;Gregory W Barsness","doi":"10.5402/2012/325092","DOIUrl":"https://doi.org/10.5402/2012/325092","url":null,"abstract":"<p><p>Thyroid disease is a common condition, and thyroid hormone excess or deficiency is known to have wide-ranging effects on a variety of organ systems. Our objective is to describe the magnitude, biochemical features, and clinical characteristics of hepatic abnormalities in patients with acute thyrotoxicosis. We performed a retrospective review of all patients admitted to our institution between January 1, 1998 and December 31, 2008 with a discharge diagnosis of acute thyrotoxicosis excluding iatrogenic causes. The records of these patients were reviewed and data extracted regarding demographic, biochemical, and clinical data particularly relevant to liver function. Fourteen patients were identified of which eleven had liver studies performed. The majority (90.9%) had Graves disease. Nine of eleven patients (81.8%) had some degree of hepatic abnormality. Seven patients (63.6%) had an elevation in one or both transaminases, and two (18.2%) had isolated synthetic dysfunction as manifested as an elevated INR and/or decreased albumin without transaminitis. The mean magnitude of deviation from the normal range was greater in the transaminases as compared to bilirubin, INR, or albumin. Definitive treatment was radioiodine ablation in six cases (54.5%) and surgical thyroidectomy in two cases (18.2%). Noniatrogenic acute thyrotoxicosis requiring hospitalization is a rare condition which is most frequently caused by Graves disease. The majority of patients have disordered liver tests of a highly variable nature, making the recognition of this association important in the care of patients presenting with acute thyrotoxicosis.</p>","PeriodicalId":89576,"journal":{"name":"ISRN endocrinology","volume":"2012 ","pages":"325092"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5402/2012/325092","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31133999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 37
Hypoglycemic Effect of Laminaria japonica Polysaccharide in a Type 2 Diabetes Mellitus Mouse Model. 海带多糖对2型糖尿病小鼠模型的降糖作用。
ISRN endocrinology Pub Date : 2012-01-01 Epub Date: 2012-10-30 DOI: 10.5402/2012/507462
Xiaodan Li, Zhuqin Yu, Shaohua Long, Yunliang Guo, Delin Duan
{"title":"Hypoglycemic Effect of Laminaria japonica Polysaccharide in a Type 2 Diabetes Mellitus Mouse Model.","authors":"Xiaodan Li,&nbsp;Zhuqin Yu,&nbsp;Shaohua Long,&nbsp;Yunliang Guo,&nbsp;Delin Duan","doi":"10.5402/2012/507462","DOIUrl":"https://doi.org/10.5402/2012/507462","url":null,"abstract":"<p><p>The aim is to investigate the hypoglycemic effect of Laminaria japonica polysaccharides (LJPS) on type 2 diabetes mellitus (T2DM) mice model. 60 healthy male mice have been used in the experiment. T2DM animal mode was prepared by high fatty forage feeding and intraperitoneal injection with alloxan. Diabetic mice were orally supplied with LJPS. Then their blood was collected for various biomedical measurements of fasting blood glucose (FBG), serum insulin, and amylin. Treatment with LJPS significantly reduced fasting blood glucose (P < 0.05) and increased the levels of insulin and amylin in serum (P < 0.05). Overall, the study presented that LJPS can reverse several components of T2DM. Therefore, LJPS may become a new oral candidate medicine for the treatment of diabetes.</p>","PeriodicalId":89576,"journal":{"name":"ISRN endocrinology","volume":"2012 ","pages":"507462"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5402/2012/507462","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31094663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 24
Mass spectrometry for diabetic nephropathy monitoring: new effective tools for physicians. 质谱法监测糖尿病肾病:医生新的有效工具。
ISRN endocrinology Pub Date : 2012-01-01 Epub Date: 2012-05-20 DOI: 10.5402/2012/768159
Annunziata Lapolla, Simona Porcu, Pietro Traldi
{"title":"Mass spectrometry for diabetic nephropathy monitoring: new effective tools for physicians.","authors":"Annunziata Lapolla,&nbsp;Simona Porcu,&nbsp;Pietro Traldi","doi":"10.5402/2012/768159","DOIUrl":"https://doi.org/10.5402/2012/768159","url":null,"abstract":"<p><p>The main aim of diabetic nephropathy monitoring is to identify molecular markers, that is, to find changes occurring at metabolome and proteome levels indicative of the disease's development. The mass spectrometry methods available today have been successfully applied to this field. This paper provides a short description of the basic aspects of the mass spectrometric methods used for diabetic nephropathy monitoring, reporting and discussing the results obtained using different approaches.</p>","PeriodicalId":89576,"journal":{"name":"ISRN endocrinology","volume":"2012 ","pages":"768159"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5402/2012/768159","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30680634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Quick and simple evaluation of sudomotor function for screening of diabetic neuropathy. 快速、简便地评估sudymotor功能筛查糖尿病神经病变。
ISRN endocrinology Pub Date : 2012-01-01 Epub Date: 2012-07-09 DOI: 10.5402/2012/103714
Chittaranjan S Yajnik, Vaishali V Kantikar, Amol J Pande, Jean P Deslypere
{"title":"Quick and simple evaluation of sudomotor function for screening of diabetic neuropathy.","authors":"Chittaranjan S Yajnik,&nbsp;Vaishali V Kantikar,&nbsp;Amol J Pande,&nbsp;Jean P Deslypere","doi":"10.5402/2012/103714","DOIUrl":"https://doi.org/10.5402/2012/103714","url":null,"abstract":"<p><p>Objective. The aim of this study was to compare SUDOSCAN, a new device to evaluate sweat function (reflecting peripheral small C-fiber status), with conventional measures of peripheral and cardiac neuropathy in patients with type 2 diabetes. Methods. 265 diabetic patients were tested for symptoms and clinical signs of neuropathy using Michigan Neuropathy Screening Instrument (MNSI), vibration perception threshold (VPT) using biothesiometer, and cardiac autonomic neuropathy (CAN) using Ewing's protocol. Sudomotor function was investigated with SUDOSCAN through measurement of electrochemical skin conductance (ESC) of hands and feet. Lower ESC is suggestive of sudomotor dysfunction. Results. Lower ESC at feet was significantly associated both with increasing symptoms (MNSI A) and increasing score on physical abnormalities (MNSI B). Lower ESC at feet was also significantly associated with increasing VPT by biothesiometry (P < 0.01), and with higher number of abnormal CAN results (P < 0.05). ESC was associated with postural fall in blood pressure (sympathetic abnormality) (P < 0.05), but not with heart rate variability (HRV) tests (parasympathetic abnormalities). Conclusions. Sudomotor dysfunction testing may be a simple test to alert physicians to peripheral nerve and cardiac sympathetic dysfunction. Ease of performance could make it useful in a busy diabetic clinic. Further studies with hard clinical outcomes are indicated.</p>","PeriodicalId":89576,"journal":{"name":"ISRN endocrinology","volume":"2012 ","pages":"103714"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5402/2012/103714","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30788502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 91
Sterculic Oil, a Natural SCD1 Inhibitor, Improves Glucose Tolerance in Obese ob/ob Mice. 甾体油,一种天然SCD1抑制剂,改善肥胖ob/ob小鼠的葡萄糖耐量。
ISRN endocrinology Pub Date : 2012-01-01 Epub Date: 2012-11-14 DOI: 10.5402/2012/947323
Laura C Ortinau, R Taylor Pickering, Karen J Nickelson, Kelly L Stromsdorfer, Chaitasi Y Naik, Rebecca A Haynes, Dale E Bauman, R Scott Rector, Kevin L Fritsche, James W Perfield
{"title":"Sterculic Oil, a Natural SCD1 Inhibitor, Improves Glucose Tolerance in Obese ob/ob Mice.","authors":"Laura C Ortinau,&nbsp;R Taylor Pickering,&nbsp;Karen J Nickelson,&nbsp;Kelly L Stromsdorfer,&nbsp;Chaitasi Y Naik,&nbsp;Rebecca A Haynes,&nbsp;Dale E Bauman,&nbsp;R Scott Rector,&nbsp;Kevin L Fritsche,&nbsp;James W Perfield","doi":"10.5402/2012/947323","DOIUrl":"https://doi.org/10.5402/2012/947323","url":null,"abstract":"<p><p>Obesity and its metabolic complications are associated with increased expression/activity of stearoyl-CoA desaturase-1 (SCD1), a major regulator of lipid metabolism. Reduction or ablation of this enzyme is associated with an improved metabolic profile and has gained attention as a target for pharmaceutical development. Sterculic oil (SO) is a known inhibitor of SCD1 and may provide a natural approach for treating obesity and/or insulin resistance. The purpose of this study was to evaluate the effects of SO consumption in leptin-deficient ob/ob mice, a model of obesity and insulin resistance. Five-week-old male mice received either an AIN-93G (control) or an AIN-93G diet containing 0.5% SO. After 9 weeks, SO supplementation did not alter food intake or body weight; however, the desaturase indices, a proxy of SCD1 activity, were reduced in liver and adipose tissue of SO-supplemented animals. This reduction was associated with improved glucose and insulin tolerance and attenuated hepatic inflammation in obese ob/ob mice, while no appreciable changes were observed in lean control mice receiving SO. Future studies are needed to better understand the mechanism(s) by which SO is functioning to improve glucose metabolism and to further explore the nutraceutical potential and health implications of SO supplementation.</p>","PeriodicalId":89576,"journal":{"name":"ISRN endocrinology","volume":"2012 ","pages":"947323"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5402/2012/947323","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31094665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 25
Differences in Expression, Content, and Activity of 11β-HSD1 in Adipose Tissue between Obese Men and Women. 肥胖男女脂肪组织中11β-HSD1表达、含量和活性的差异
ISRN endocrinology Pub Date : 2012-01-01 Epub Date: 2012-12-09 DOI: 10.5402/2012/787201
A Torres, G Iñiguez, M Ferrario, V Mericq
{"title":"Differences in Expression, Content, and Activity of 11β-HSD1 in Adipose Tissue between Obese Men and Women.","authors":"A Torres,&nbsp;G Iñiguez,&nbsp;M Ferrario,&nbsp;V Mericq","doi":"10.5402/2012/787201","DOIUrl":"https://doi.org/10.5402/2012/787201","url":null,"abstract":"<p><p>Cortisol production in adipose tissue is regulated by 11β-HSD1. Objective. To determine whether there are differences in gene expression, enzyme activity, and protein content of the 11β-HSD1 enzyme in VAT (visceral adipose tissue) and SAT (subcutaneous adipose tissue) from obese compared to nonobese adults. Methods. VAT and SAT samples were obtained from 32 obese subjects (BMI > 30 Kg/m(2)) who underwent bariatric surgery and 15 samples from controls submitted to elective surgery. Fasting serum glucose, insulin, and lipids were measured. The expression of 11β-HSD1 was determined by RT-PCR, the enzyme activity by thin-layer chromatography, and the protein content by Western blot. Results. Obese patients had higher cholesterol, insulin, and HOMA-IR compared to nonobese. There were no differences in VAT or SAT expression of 11β-HSD1 between obese and nonobese patients. However, we found lower 11β-HSD1 activity and protein content in VAT, in obese women versus nonobese women (P < 0.05). BMI and 11β-HSD1 enzyme activity and protein content in VAT correlated inversely in women. Conclusions. Regulation of 11β-HSD1 activity in VAT from obese subjects appears to be gender specific, suggesting the existence of a possible protective mechanism modulating this enzyme activity leading to a decrease in the production of cortisol in this tissue.</p>","PeriodicalId":89576,"journal":{"name":"ISRN endocrinology","volume":"2012 ","pages":"787201"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5402/2012/787201","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31151841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis. 各种抗糖尿病药物作为二甲双胍治疗2型糖尿病的疗效:系统评价和荟萃分析。
ISRN endocrinology Pub Date : 2012-01-01 Epub Date: 2012-03-27 DOI: 10.5402/2012/798146
Nalinee Poolsup, Naeti Suksomboon, Wanwaree Setwiwattanakul
{"title":"Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis.","authors":"Nalinee Poolsup,&nbsp;Naeti Suksomboon,&nbsp;Wanwaree Setwiwattanakul","doi":"10.5402/2012/798146","DOIUrl":"https://doi.org/10.5402/2012/798146","url":null,"abstract":"<p><p>Background and Aim. Diabetes mellitus is a chronic disease that has a great impact on patients and society. Metformin monotherapy is capable of maintaining a target glycemic control only for a short term. The aim of this study was to determine the efficacy of combination therapy of metformin with any antidiabetic agents in type 2 diabetes mellitus (T2DM) patients. Methods. Reports of randomized controlled trials (RCTs) of combination therapy of metformin with various antidiabetic agents in T2DM failing metformin alone were identified. Results. Eight studies were identified in our paper. Thiazolidinediones (TZDs) were as effective as dipeptidyl peptidase IV inhibitors (DPP IV inhs) in reducing HbA1c value (pooled mean difference -0.03%; 95% CI -0.16 to 0.10%). In comparison between TZDs and sulphonylureas (SUs), TZDs reduced fasting plasma insulin (FPI) more effectively than SUs (pool mean difference -5.72 μU/mL; 95% CI -8.21 to -3.22 μU/mL, P < 0.00001), but no significant differences were detected in the effects on HbA1c and fasting plasma glucose (FPG) (pooled mean difference -2.19 mg/dL; 95% CI -11.32 to 6.94 mg/dL, P = 0.64). Conclusions. Our study showed that TZDs reduced FPG better than did DPP IV inhs and decreased FPI more than did SUs.</p>","PeriodicalId":89576,"journal":{"name":"ISRN endocrinology","volume":"2012 ","pages":"798146"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5402/2012/798146","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30638361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Serum levels of fetal antigen 1 in extreme nutritional States. 极端营养状态下胎儿抗原1的血清水平。
ISRN endocrinology Pub Date : 2012-01-01 Epub Date: 2012-07-15 DOI: 10.5402/2012/592648
Alin Andries, Andreas Niemeier, Rene K Støving, Basem M Abdallah, Anna-Maria Wolf, Kirsten Hørder, Moustapha Kassem
{"title":"Serum levels of fetal antigen 1 in extreme nutritional States.","authors":"Alin Andries,&nbsp;Andreas Niemeier,&nbsp;Rene K Støving,&nbsp;Basem M Abdallah,&nbsp;Anna-Maria Wolf,&nbsp;Kirsten Hørder,&nbsp;Moustapha Kassem","doi":"10.5402/2012/592648","DOIUrl":"https://doi.org/10.5402/2012/592648","url":null,"abstract":"<p><p>Objective. Recent data suggest that fetal antigen (FA1) is linked to disorders of body weight. Thus, we measured FA1 serum levels in two extreme nutritional states of morbid obesity (MO) and anorexia nervosa (AN) and monitored its response to weight changes. Design. FA1 and insulin serum concentrations were assessed in a cross-sectional study design at defined time points after gastric restrictive surgery for 25 MO patients and 15 women with AN. Results. Absolute FA1 serum levels were within the assay normal range and were not different between the groups at baseline. However, the ratio of FA1/BMI was significantly higher in AN. FA1 was inversely correlated with BMI before and after weight change in AN, but not in MO patients. In addition, MO patients displayed a significant concomitant decrease of FA1 and insulin with the first 25% of EWL, while in AN patients a significant increase of FA1 was observed in association with weight gain. Conclusion. FA1 is a sensitive indicator of metabolic adaptation during weight change. While FA1 serum levels in humans generally do not correlate with BMI, our results suggest that changes in FA1 serum levels reflect changes in adipose tissue turnover.</p>","PeriodicalId":89576,"journal":{"name":"ISRN endocrinology","volume":"2012 ","pages":"592648"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5402/2012/592648","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30798962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信